Pharmacy Times
JULY 16, 2025
14,15 Lung Cancer Tarlatamab Significantly Improves Survival in Patients With Small Cell Lung Cancer Post Progression Tarlatamab has shown promising efficacy in relapsed SCLC based on the initial single-arm trial findings, leading to an FDA approval in 2024, but challenges with administration have limited its widespread adoption.
Pharmacy Times
JUNE 27, 2025
5 Phase 3 ECHO Trial: A New Frontline Option The approval was supported by data from the phase 3 ECHO trial (NCT02972840), presented at the 2024 European Hematology Association Hybrid Congress. June 21, 2024. Deaths were reported in 5 TN and 6 R/R patients. The trial enrolled 598 patients 65 years or older with TN MCL. Hemasphere.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Pharmacy Times
JULY 21, 2025
Fournier, BSc Key Takeaways The 2024-2025 influenza season saw unprecedented severity, with high hospitalization and outpatient visit rates due to a vaccine mismatch and dominant H1N1 and H3N2 strains. 2 From October 2024 to March 2025, the CDC reported at least 37 million influenza infections, 480,000 hospitalizations, and 21,000 deaths.
Pharmacy Times
JUNE 20, 2025
Prior to October 2024, the Advisory Committee on Immunization Practices (ACIP) recommended use of a PCV only for all adults aged 65 years and older, including those aged 19 to 64 years with risk conditions for pneumococcal disease.
Pharmacy Times
JUNE 24, 2025
Updated April 2, 2024. A study of JNJ-68284528, a chimeric antigen receptor T cell (CAR-T) therapy directed against B-cell maturation antigen (BCMA) in participants with relapsed or refractory multiple myeloma (CARTITUDE-1). Accessed June 24, 2025.
Pharmacy Times
JUNE 4, 2025
Difficile COPD COVID-19 Cardiovascular Health Cervical Cancer Cholangiocarcinoma Cholesterol Chronic Kidney Disease Chronic Lymphocytic Leukemia Classical Hematology Colorectal Cancer Continuous Glucose Monitoring Cough and Cold Depression Dermatology Diabetes Digestive Health Dry Eye Disease Epilepsy Eye Care Flu Future of Pharmacy Gastrointestinal (..)
Pharmacy Times
JUNE 16, 2025
The FDA approved nemolizumab in December 2024 for the treatment of moderate-to-severe atopic dermatitis in combination with topical corticosteroids and/or calcineurin inhibitors when the disease is not controlled by topical prescription therapies among individuals 12 and older. May 15, 2024. Pharmacy Times. December 16, 2024.
Expert insights. Personalized for you.
Let's personalize your content